Press Releases

• December 20, 2022
  

  C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform

  C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).

• December 8, 2022
  

  ‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases

  A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit.

• December 7, 2022
  

  C-Path Receives Data Transfer from Network of Hospitals in Japan

  C-Path has received properly anonymized electronic patient record (EPR) data from three hospitals in the Neonatal Research Network of Japan — Nagano Children’s Hospital, Kyorin University and Osaka General Hospital. The collaboration comes from partnering with leading pediatric neonatologists, Dr. Tomohiko Nakamura, Dr. Kenichiro Hosoi and Dr. Hiroko Iwami at each site, respectively.

• December 1, 2022
  

  C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies

  C-Path and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).

• November 15, 2022
  

  C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias

  The Critical Path for Alzheimer’s Disease (CPAD) at the Critical Path Institute (C-Path) and Cerveau Technologies, Inc. are proud to announce a data sharing collaboration to advance the scientific understanding of disease pathology and progression and enable development of novel quantitative Drug Development Tools in Alzheimer’s disease (AD) and related dementias.